Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells

Life Sciences

Volumn 86, Issue 5-6, 2010, Pages 214-223

  Bai, Xiao Ming ^a   Jiang, Hui ^b   Ding, Jing Xian ^a   Peng, Tao ^a   Ma, Juan ^a   Wang, Yao Hui ^a   Zhang, Li ^a   Zhang, Hai ^a   Leng, Jing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Department of Vascular Surgery   (China)

Author keywords

EP1 receptor; Hepatocellular carcinoma; Prostaglandin E2; Survivin

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CELECOXIB; CYCLOOXYGENASE 2; E PROSTANOID 1; E PROSTANOID 1 RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMID DNA; PROSTAGLANDIN E2; PROSTANOID; PROSTANOID RECEPTOR; PROTEIN KINASE B; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; PROSTAGLANDIN E RECEPTOR; PROSTANOID RECEPTOR EP1;

ARTICLE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TRANSACTIVATION; UPREGULATION; BIOSYNTHESIS; CELL PROLIFERATION; DRUG POTENTIATION; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; LIVER NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; PLASMIDS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PROSTAGLANDIN E; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION;

EID: 74749083984     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.12.009     Document Type: Article

References (51)

1. Asanuma H., Torigoe T., Kamiguchi K., Hirohashi Y., Ohmura T., Hirata K., Sato M., Sato N. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Research 2005, 65(23):11018-11025.
2. Atikcan S., Unsal E., Demirag F., Koksal D., Yilmaz A. Correlation between survivin expression and prognosis in non-small cell lung cancer. Respiratory Medicine 2006, 100(12):2220-2226.
3. Bai X.M., Zhang W., Liu N.B., Jiang H., Lou K.X., Peng T., Ma J., Zhang L., Zhang H., Leng J. Focal adhesion kinase: important to prostaglandin E2-mediated adhesion, migration and invasion in hepatocellular carcinoma cells. Oncology Reports 2009, 21:129-136.
4. 2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells. Journal of Leukocyte Biology 2005, 78(2):555-564.
5. Barnes N., Haywood P., Flint P., Knox W.F., Bundred N.J. Survivin expression in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. British Journal of Cancer 2006, 94(2):253-258.
6. Basu G.D., Pathangey L.B., Tinder T.L., Gendler S.J., Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Research 2005, 7(4):R422-R435.
7. Buchanan F.G., Wang D., Bargiacchi F., DuBois R.N. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. The Journal of Biological Chemistry 2003, 278(37):35451-35457.
8. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tomsik J., Elton T.S., Simmons D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(21):13926-13931.
9. Cui W., Yu C.H., Hu K.Q. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clinical Cancer Research 2005, 11(22):8213-8221.
10. Dohadwala M., Luo J., Zhu L., Lin Y., Dougherty G.J., Sharma S., Huang M., Põld M., Batra R.K., Dubinett S.M. Non-small cell lung cancer Cyclooxygenase-2-dependent invasion is mediated by CD44. The Journal of Biological Chemistry 2001, 276(24):20809-20812.
11. Erkanli S., Bolat F., Kayaselcuk F., Demirhan B., Kuscu E. COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecologic Oncology 2007, 104(2):320-325.
12. Fields A.C., Cotsonis G., Sexton D., Santoianni R., Cohen C. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Modern Pathology 2004, 17(11):1378-1385.
13. Fischer O.M., Hart S., Gschwind A., Ullrich A. EGFR signal transactivation in cancer cells. Biochemical Society Transactions 2003, 31(Pt 6):1203-1208.
14. Futakuchi H., Ueday M., Kanda K., Fujino K., Yamaguchi H., Noda S. Transcriptional expression of survivin and its splice variants in cervical carcinomas. International Journal of Gynecological Cancer 2007, 17(5):1092-1098.
15. Grossman E.M., Longo W.E., Panesar N., Mazuski J.E., Kaminski D.L. The role of cyclooxygenase enzymes in the growth of human gall bladder cancer cells. Carcinogenesis 2000, 21(7):1403-1409.
16. Han C., Michalopoulos G.K., Wu T. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. Journal of Cellular Physiology 2006, 207(1):261-270.
17. Han C., Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. The Journal of Biological Chemistry 2005, 280(25):24053-24063.
18. Hussain T., Gupta S., Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Letters 2003, 191(2):125-135.
19. Ito T., Shiraki K., Sugimoto K., Yamanaka T., Fujikawa K., Ito M., Takase K., Moriyama M., Kawano H., Hayashida M., Nakano T., Suzuki A. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000, 31(5):1080-1085.
20. Kiriyama M., Ushikubi F., Kobayashi T., Hirata M., Sugimoto Y., Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. British Journal of Pharmacology 1997, 122(2):217-224.
21. Konturek P.C., Rembiasz K., Burnat G., Konturek S.J., Tusinela M., Bielanski W., Rehfeld J., Karcz D., Hahn E. Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. Digestive Diseases and Sciences 2006, 51(4):779-787.
22. Krysan K., Merchant F.H., Zhu L., Dohadwala M., Luo J., Lin Y., Heuze-Vourc'h N., Põld M., Seligson D., Chia D., Goodglick L., Wang H., Strieter R., Sharma S., Dubinett S. COX-2-dependent stabilization of survivin in non-small cell lung cancer. The Journal of the Federation of American Societies for Experimental Biology 2003, 18(1):206-208.
23. Krysan K., Dalwadi H., Sharma S., Põld M., Dubinett S. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Research 2004, 64(18):6359-6362.
24. Lee M.A., Park G.S., Lee H.J., Jung J.H., Kang J.H., Hong Y.S., Lee K.S., Kim D.G., Kim S.N. Survivin expression and its clinical significance in pancreatic cancer. BioMed Central Cancer 2005, 5:127.
25. Leng J., Han C., Demetris A.J., Michalopoulos G.K., Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003, 38(3):756-768.
26. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., Altieri D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396(6711):580-584.
27. Liu N.B., Peng T., Pan C., Yao Y.Y., She B., Leng J. Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis. World Journal of Gastroenterology 2005, 11(40):6281-6287.
28. Martineau L.C., McVeigh L.I., Jasmin B.J., Kennedy C.R. p38 MAP kinase mediates mechanically induced COX-2 and PG EP4 receptor expression in podocytes: implications for the actin cytoskeleton. American Journal of Physiology-Renal Physiology 2004, 286(4):F693-701.
29. Mayoral R., Fernandez-Martínez A., Bosca L., Martín-Sanz P. Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis 2005, 26(4):753-761.
30. Mori F., Piro F.R., Della Rocca C., Mesiti G., Giampaoli S., Silvestre G., Lazzaro D. Survivin and Cyclooxygenase-2 are co-expressed in human and mouse colon carcinoma and in terminally differentiated colonocytes. Histology and Histopathology 2007, 22(1):61-77.
31. Morinaga S., Nakamura Y., Ishiwa N., Yoshikawa T., Noguchi Y., Yamamoto Y., Rino Y., Imada T., Takanashi Y., Akaike M., Sugimasa Y., Takemiya S. Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. Oncology Reports 2004, 12(6):1189-1194.
32. Nakamura S., Kobayashi M., Shibata K., Sahara N., Shigeno K., Shinjo K., Naito K., Hayashi H., Ohnishi K. Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells. Leukemia Research 2006, 30(2):123-135.
33. Nakao K., Hamasaki K., Ichikawa T., Arima K., Eguchi K., Ishii N. Survivin downregulation by siRNA sensitizes human hepatoma cells to TRAIL-induced apoptosis. Oncology Reports 2006, 16(2):389-392.
34. O'Callaghan G., Kelly J., Shanahan F., Houston A. Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells. British Journal of Cancer 2008, 99(3):502-512.
35. Perez S., Maldonado E.N., Aspichueta P., Ochoa B., Chico Y. Differential modulation of prostaglandin receptor mRNA abundance by prostaglandins in primary cultured rat hepatocytes. Molecular and Cellular Biochemistry 2004, 266(1-2):183-189.
36. Sakoguchi-Okada N., Takahashi-Yanaga F., Fukada K., Shiraishi F., Taba Y., Miwa Y., Morimoto S., Iida M., Sasaguri T. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochemical Pharmacology 2007, 73(9):1318-1329.
37. Sandler A.B., Dubinett S.M. COX-2 inhibition and lung cancer. Seminars in Oncology 2004, 31(2 Suppl 7):45-52.
38. Shariat S.F., Ashfaq R., Karakiewicz P.I., Saeedi O., Sagalowsky A.I., Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007, 109(6):1106-1113.
39. Smith W.L., Langenbach R. Why there are two cyclooxygenase isozymes. The Journal of Clinical Investigation 2001, 107(12):1491-1495.
40. Sugimoto Y., Narumiya S. Prostaglandin E receptors. The Journal of Biological Chemistry 2007, 282(16):11613-11617.
41. Suzuki A., Hayashida M., Ito T., Kawano H., Nakano T., Miura M., Akahane K., Shiraki K. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16INK4a and Cdk2/Cyclin E complex activation. Oncogene 2000, 19(29):3225-3234.
42. Ushikubi F., Sugimoto Y., Ichikawa A., Narumiya S. Roles of prostanoids revealed from studies using mice lacking specific prostanoid receptors. Japanese Journal of Pharmacology 2000, 83(4):279-285.
43. Wendum D., Masliah J., Trugnan G., Flejou J.F. Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Archiv: An International Journal of Pathology 2004, 445(4):327-333.
44. Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treatment Reviews 2006, 32(1):28-44.
45. Wu T., Leng J., Han C., Demetris A.J. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Molecular Cancer Therapeutics 2004, 3(3):299-307.
46. Yang D., Welm A., Bishop J.M. Cell division and cell survival in the absence of survivin. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(42):15100-15105.
47. Ye C.P., Qiu C.Z., Huang Z.X., Su Q.C., Zhuang W., Wu R.L., Li X.F. Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma. World Journal of Gastroenterology 2007, 13(46):6264-6268.
48. Yonesaka K., Tamura K., Kurata T., Satoh T., Ikeda M., Fukuoka M., Nakagawa K. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. International Journal of Cancer 2006, 118(4):812-820.
49. Zha S., Yegnasubramanian V., Nelson W.G., Isaacs W.B., De Marzo A.M. Cyclooxygenases in cancer: progress and perspective. Cancer Letters 2004, 215(1):1-20.
50. Zhang L., Jiang L., Sun Q., Peng T., Lou K., Liu N., Leng J. Prostaglandin E2 enhances mitogen-activated protein kinase/Erk pathway in human cholangiocarcinoma cells: involvement of EP1 receptor, calcium and EGF receptors signaling. Molecular and Cellular Biochemistry 2007, 305(1-2):19-26.
51. Zhao Q.T., Yue S.Q., Cui Z., Wang Q., Cui X., Zhai H.H., Zhang L.H., Dou K.F. Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. Life Sciences 2007, 80(5):484-492.